Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ProMIS Neurosciences (PMN) will begin trading on Nasdaq under the symbol PMN on July 8
  • Common shares of ProMIS Neurosciences will continue to trade on the Toronto Stock Exchange (TSX) under its current symbol
  • The  common shares of the company will cease to be quoted on the OTCQB
  • ProMIS Neurosciences Inc. is a development-stage biotechnology company
  • ProMIS Neurosciences Inc. opened trading at $8.22 per share

ProMIS Neurosciences (PMN) has received approval from The Nasdaq Capital Market LLC to list its common shares on Nasdaq.

Effective July 8, the company’s common shares will begin trading on Nasdaq under the symbol PMN.

Common shares of ProMIS Neurosciences will continue to trade on the Toronto Stock Exchange (TSX) under its current symbol.

The company’s common shares will cease to be quoted on the OTCQB.

“The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly traded company,” stated Eugene Williams, Chairman and CEO of ProMIS.

“We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value,” he added.

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

ProMIS Neurosciences Inc. opened trading at $8.22 per share.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.